Darmstadt, Germany

Lisa Koetzner

This inventor holds 1 USPTO granted patent and 7 published patent applications and 2 EPO patents. Top assignees: Merck Patent Gmbh, Ryvu Therapeutics S.a.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lisa Koetzner. Retrieved from https://idiyas.com/inventor/lisa-koetzner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lisa Koetzner: Innovator in Medical Research

Introduction: Lisa Koetzner is an accomplished inventor based in Darmstadt, Germany. She has made significant contributions to the field of medical research, particularly in the development of novel compounds for the treatment of various medical conditions. Although she currently holds no granted patents, her work is noteworthy for its potential impact on healthcare.

Latest Patent Applications: Lisa Koetzner's latest patent applications include innovative compounds such as substituted tetrazole derivatives. These derivatives are useful for the prevention and/or treatment of several medical conditions, including hyperproliferative disorders and diseases. Another application involves tricyclic heterocycles, which are disclosed as useful TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interactions. These compounds also aim to address medical conditions, particularly cancer.

Conclusion: Lisa Koetzner's work exemplifies the spirit of innovation in medical research, and her ongoing efforts may lead to significant advancements in treatment options for various diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…